In this Issue:
Upstaging negative lymph nodes with OSNA
Prognostic impact of TRG in rectal cancer
Cetuximab no benefit for resectable liver metastases
Secondary resection of liver metastases improves survival
High-level microsatellite instability in mCRC
Panitumumab non-inferior to cetuximab in mCRC
RAC1b overexpression correlates with poor prognosis
Biomarker assessment in clinical trial design
Continuous vs intermittent cetuximab in mCRC
PET–CT vs CT for resectabilityof liver metastases
Please login below to download this issue (PDF)